CAR-T Meeting 2024 | CAR-Tregs hold potential for the treatment of autoimmune disease
Matteo Doglio, MD, PhD, IRCCS Ospedale San Raffaele, Milan, Italy, discusses the two potential approaches for using CAR T-cell therapy to treat autoimmune disease (AID). Conventional CAR-T is being utilized in studies to deplete autoreactive cells, and CAR-Treg cells are being tested in an attempt to control autoimmune cells and restore immune tolerance. Dr Doglio highlights that a CAR-Treg product has been shown to work in vitro and in vivo in mouse models, suggesting that this approach may be feasible in the future. However, these products are still in the early stages of development and have not yet been infused into patients. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
